| Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. | |
| | |
MedLine Citation:
|
PMID: 19329543 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The British Association for Psychopharmacology guidelines specify the scope and target of treatment for bipolar disorder. The second version, like the first, is based explicitly on the available evidence and presented, like previous Clinical Practice guidelines, as recommendations to aid clinical decision making for practitioners: they may also serve as a source of information for patients and carers. The recommendations are presented together with a more detailed but selective qualitative review of the available evidence. A consensus meeting, involving experts in bipolar disorder and its treatment, reviewed key areas and considered the strength of evidence and clinical implications. The guidelines were drawn up after extensive feedback from participants and interested parties. The strength of supporting evidence was rated. The guidelines cover the diagnosis of bipolar disorder, clinical management, and strategies for the use of medicines in treatment of episodes, relapse prevention and stopping treatment. |
| | |
Authors:
|
G M Goodwin; |
Related Documents
:
|
15056503 - Management of bipolar disorder during pregnancy and the postpartum period. 20868643 - Comorbid anxiety in children and adolescents with bipolar spectrum disorders: prevalenc... 15060403 - Hiv risk behavior among psychiatric outpatients: association with psychiatric disorder,... |
Publication Detail:
|
Type: Journal Article; Practice Guideline Date: 2009-03-27 |
Journal Detail:
|
Title: Journal of psychopharmacology (Oxford, England) Volume: 23 ISSN: 0269-8811 ISO Abbreviation: J. Psychopharmacol. (Oxford) Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-05-12 Completed Date: 2009-08-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8907828 Medline TA: J Psychopharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 346-88 Citation Subset: IM |
Affiliation:
|
University Department of Psychiatry, Warneford Hospital, Oxford, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antidepressive Agents
/
therapeutic use* Antimanic Agents / therapeutic use* Antipsychotic Agents / therapeutic use* Bipolar Disorder* / diagnosis, drug therapy, prevention & control, therapy Combined Modality Therapy Consensus Consensus Development Conferences as Topic Drug Therapy, Combination Evidence-Based Medicine / standards* Health Planning Guidelines* Humans Psychotherapy Recurrence / prevention & control |
| Chemical | |
Reg. No./Substance:
|
0/Antidepressive Agents; 0/Antimanic Agents; 0/Antipsychotic Agents |
| Investigator | |
Investigator/Affiliation:
|
Susan Chandler / ; Ian Anderson / ; Francesc Colom / ; David Coghill / ; John Cookson / ; Nicol Ferrier / ; John Geddes / ; Guy Goodwin / ; Peter Haddad / ; Neil Hunt / ; Nav Kapur / ; Ian Jones / ; Dominic Lam / ; Anne Lingford-Hughes / ; David Miklowitz / ; Richard Morriss / ; Barbara Sahakian / ; Jan Scott / ; David Taylor / ; Jogin Thakore / ; Anita Thapar / ; Alan Thomas / ; Philip McGuire / ; Stephen Cooper / ; Philip Cowen / ; Chris Manning / ; Klaus Ebmeier / ; Jonathan Cavanagh / ; Thomas Barnes / ; Katheine J Aitchison / |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A SMN missense mutation complements SMN2 restoring snRNPs and rescuing SMA mice.
Next Document: Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated admi...